Mutation in fallopian tube lesions may help catch ovarian cancer years earlier
(University of Pennsylvania School of Medicine) Screening for tumor cells in the fallopian tubes of women at high-risk for ovarian cancer may help detect the cancer years before it develops further, suggests a new study published online this week in Nature Communications. The new study traces the origins of high-grade serous ovarian carcinoma, the most frequent type of ovarian cancer that is often diagnosed at advanced stages, back to fallopian tube lesions known as 'p53 signatures' and serous tubal intraepithelial carcinomas (STICs) that harbor the TP53 gene mutations. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 26, 2017 Category: Cancer & Oncology Source Type: news
To Prevent Ovarian Cancer, Focus on the Fallopian Tube To Prevent Ovarian Cancer, Focus on the Fallopian Tube
New data support the rationale to focus on the distal fallopian tube when considering surgical or medical approaches to prevent high-grade serous ovarian cancer, researchers say.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 18, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Ovarian Fallopian Tube Primary Peritoneal Cancer
Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Prevention (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 27, 2017 Category: General Medicine Source Type: news
ovarian epithelial fallopian cancer
Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 27, 2017 Category: General Medicine Source Type: news
It ’ s your body, it ’ s your choice – Louise ’ s story
I woke up the day after my work Christmas party with, not the raging hangover some of my colleagues might have, but dreadful pains across my lower half, the small of my back and down my left leg. My period was due, and being 48, I thought this could be the peri-menopause too! Joys of being a woman! But I really didn’t give it an awful lot of thought.
But the pains got worse. I was working as a teacher in Hanoi, Vietnam where all healthcare is paid for, and appointments are always available. I got an appointment the next day and was seen immediately by a gynaecologist, who said “I know what this is!” The ultrasound re...
Source: The Hysterectomy Association - April 10, 2017 Category: OBGYN Authors: Linda Parkinson-Hardman Tags: Health endometriosis hysterectomy stories ovarian cyst Source Type: news
It ’ s your body, it ’ s your choice – Louise ’ s story
I woke up the day after my work Christmas party with, not the raging hangover some of my colleagues might have, but dreadful pains across my lower half, the small of my back and down my left leg. My period was due, and being 48, I thought this could be the peri-menopause too! Joys of being a woman! But I really didn’t give it an awful lot of thought.
But the pains got worse. I was working as a teacher in Hanoi, Vietnam where all healthcare is paid for, and appointments are always available. I got an appointment the next day and was seen immediately by a gynaecologist, who said “I know what this is!” The ultrasound re...
Source: The Hysterectomy Association - April 10, 2017 Category: OBGYN Authors: Linda Parkinson-Hardman Tags: Health endometriosis hysterectomy stories ovarian cyst Source Type: news
It ’ s your body, it ’ s your choice – Louise ’ s story
The post It’s your body, it’s your choice – Louise’s story appeared first on Hysterectomy Association.
I woke up the day after my work Christmas party with, not the raging hangover some of my colleagues might have, but dreadful pains across my lower half, the small of my back and down my left leg. My period was due, and being 48, I thought this could be the peri-menopause too! Joys of being a woman! But I really didn’t give it an awful lot of thought.
But the pains got worse. I was working as a teacher in Hanoi, Vietnam where all healthcare is paid for, and appointments are always available. I got...
Source: The Hysterectomy Association - April 10, 2017 Category: OBGYN Authors: Linda Tags: Your Stories endometriosis ovarian cyst Source Type: news
It ’ s your body, it ’ s your choice – Louise ’ s story
I woke up the day after my work Christmas party with, not the raging hangover some of my colleagues might have, but dreadful pains across my lower half, the small of my back and down my left leg. My period was due, and being 48, I thought this could be the peri-menopause too! Joys of being a woman! But I really didn’t give it an awful lot of thought.
But the pains got worse. I was working as a teacher in Hanoi, Vietnam where all healthcare is paid for, and appointments are always available. I got an appointment the next day and was seen immediately by a gynaecologist, who said “I know what this is!” The ultrasound re...
Source: The Hysterectomy Association - April 10, 2017 Category: OBGYN Authors: Linda Parkinson-Hardman Tags: Health endometriosis hysterectomy stories ovarian cyst Source Type: news
FDA Approves Niraparib for Recurrent Ovarian Cancer
The FDA announced the approval of niraparib, an oral PARP inhibitor, for the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. (Source: CancerNetwork)
Source: CancerNetwork - March 28, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Gynecologic Cancers News Ovarian Cancer Source Type: news
FDA approves maintenance treatment for recurrent epithelial ovarian, fallopian tube or primary peritoneal cancers
The U.S. Food and Drug Administration today approved Zejula (niraparib) for the maintenance treatment (intended to delay cancer growth) of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, whose tumors have completely or partially shrunk (complete or partial response, respectively) in response to platinum-based chemotherapy. (Source: Food and Drug Administration)
Source: Food and Drug Administration - March 27, 2017 Category: American Health Source Type: news
Tesaro wins FDA approval for potential blockbuster cancer drug
The FDA has approved a cancer drug developed by Waltham-based Tesaro that some analysts believe could surpass $2 billion in peak sales.
Shares of Tesaro (Nasdsaq: TSRO) were halted Monday afternoon prior to the FDA’s announcement. The drug, niraparib, will be sold under the brand name Zejula.
The 430-employee company previously said that regulators would issue a decision in mid-2017. In addition to being early, the approval is broad, covering patients with ovarian, fallopian tube, and primary… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 27, 2017 Category: American Health Authors: Max Stendahl Source Type: news
Maintenance Chemo After CR Fails to Extend Survival in Ovarian Cancer
A long-term phase III trial found that maintenance chemotherapy did not improve overall survival over surveillance among women with advanced ovarian/fallopian tube/peritoneal cancer who had a complete response to first-line therapy. (Source: CancerNetwork)
Source: CancerNetwork - March 14, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Gynecologic Cancers News Ovarian Cancer Conferences/SGO 2017 Source Type: news
Bevacizumab Approved for Another Type of Ovarian Cancer Bevacizumab Approved for Another Type of Ovarian Cancer
The latest FDA approval is for use in patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 12, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
